Short answer
Alnylam Pharmaceuticals (ALNY) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events). Chief Commercialization Officer Tolga Tanguler departing in December 2026.
Alnylam Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Chief Commercialization Officer Tolga Tanguler departing in December 2026
- Planned written separation agreement, terms not yet disclosed
- Leadership transition risk for Alnylam’s commercial execution and product launches
Item 8.01 · Other Events
- $1.0 billion share repurchase authorization, signaling capital return and potential support for ALNY’s stock
- Approximately $500 million targeted for repurchase by end-2026, with the balance planned during 2027
- No expiration date or purchase obligation, leaving execution dependent on liquidity, market price and investment opportunities
- Program may be modified, suspended or discontinued without prior notice, limiting certainty around actual share reduction
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alnylam Pharmaceuticals 8-K filings
Get the next ALNY 8-K as it lands
Follow ALNY for push alerts, or ask the research agent what this filing means.